Category: Press Releases

Intensity Therapeutics Receives Fast Track Designation from U.S. FDA for Development of INT230-6 as Treatment for Relapsed or Metastatic Triple Negative Breast Cancer

Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based approach to treat solid tumor cancers through direct injection of its proprietary therapeutic agents, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s development program evaluating INT230-6 for the treatment of patients with relapsed or… Read more »

Intensity Therapeutics Recognizes Rare Disease Day 2019

Intensity Therapeutics, Inc. joins patients, caregivers and rare disease advocates worldwide to recognize Rare Disease Day 2019, which is February 28. The main objective of the day is to raise public awareness of rare diseases, which are often severely debilitating illnesses that have a dramatic impact on patients’ lives. “Unfortunately, such diseases do not receive… Read more »

Intensity Therapeutics to Participate in Panel at 2019 BIO CEO & Investor Conference

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary technology and products to kill tumors and increase immune cell recognition of solid tumor cancers, today announced that Lewis H. Bender, President and CEO, will participate in the “Reshaping Tumor Microenvironments via Immunotherapies” panel at the 2019 BIO CEO & Investor Conference. The panel will examine… Read more »

Intensity Therapeutics Strengthens Intellectual Property Portfolio with Issuance of Several New Patents in Asia and Australia

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary technology and products to kill tumors and increase immune cell recognition of solid tumor cancers, today announced the receipt of patents protecting the Company’s technology and its lead product candidate, INT230-6, in China, Japan, Korea, Russia and Australia. All five countries have granted the Company a… Read more »

Intensity Therapeutics Highlights INT230-6 Data in Advanced Solid Tumors at Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary immune cell-activating cancer treatments, today announced  additional data from a Phase 1/2 clinical study of INT230-6, the Company’s novel lead product candidate designed for direct intratumoral injection, and preclinical research highlighting the Company’s proprietary DfuseRxSM technology were presented in a poster session  at the Society for… Read more »

Intensity Therapeutics Raises $6.5 Million in Series B Financing

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary immune cell-activating cancer treatments, today announced the completion of a $6.5 million Series B financing. Intensity plans to use the proceeds of the financing to advance the clinical development of lead product candidate INT230-6, a direct intratumoral injection that is currently being evaluated in a Phase… Read more »

Intensity Therapeutics Announces Preliminary Data from Clinical Study of INT230-6 in Advanced Solid Tumors

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary immune cell-activating cancer treatments, today announced  preliminary data from a Phase 1/2 clinical study demonstrated that INT230-6, the Company’s novel lead product candidate designed for direct intratumoral injection, was well tolerated in patients with advanced solid tumors. The data were presented in a poster session on… Read more »

Intensity Therapeutics to Present Preliminary Data from Clinical Study of INT230-6 at Upcoming Medical Conferences

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary immune cell-activating cancer treatments, today announced  that preliminary data from a Phase 1/2 clinical study of INT230-6 will be presented in poster sessions at the European Society for Medical Oncology (ESMO) 2018 Congress, which is being held October 19-23 in Munich, Germany, and the Society for… Read more »

Intensity Therapeutics, Inc. Announces Presentation on INT230-6 Clinical Study at the 2018 ASCO conference.

Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary immune cell-activating cancer treatments, today announced that an abstract highlighting progress in the INT230-6 clinical development program will be presented as a poster at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 1-5 in Chicago. “The abstract being presented at… Read more »

Mark A. Goldberg, MD, Joins Intensity Therapeutics, Inc. Board of Directors

Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immune-based drug products for direct intratumoral injection, today announced that Mark A. Goldberg, MD has been appointed to the Company’s Board of Directors effective May 1, 2018. Dr. Mark A. Goldberg recently served as president and COO of PAREXEL International, one of the world’s… Read more »